Pharminox appoints Dr Marc Hummersone to its Board of Directors
Nottingham, UK, 30 July 2010 - Pharminox Limited ("Pharminox" or "the Company"), the UK-based cancer drug discovery and development company, today announced that Dr Marc Hummersone has been appointed to the Board of Directors as Research Director. Dr Hummersone joined the Company from KuDOS Pharmaceuticals in April 2008 as Head of Chemistry.
The Company also announced that Professor Malcolm Stevens OBE, FRS is standing down from the Board and as Chief Scientific Officer and will take up the honorary position of CSO Emeritus.
In his new role, Dr Hummersone will take over full responsibility fro discovery research operations and strategy within Pharminox. Professor Stevens will continue to provide input and support on all aspects of discovery research in his capacity as CSO Emeritus.
Commenting on today's announcement, Peter Worrall, Chief Executive of Pharminox said, "Marc's appointment recognises the exceptional contribution that he has made in the two years since he came to Pharminox, both in building a high calibre discovery research team and also in refining the Company's discovery activities to focus on targeted DNA damage and inhibition of DNA repair.
"I would also like to take this opportunity to thank Malcolm Stevens for the huge contribution he has made to the development of Pharminox over the last six years. I am very pleased that Malcolm intends to retain close ties with the Company in his new role as CSO Emeritus, and that we will continue to benefit from his valuable insights and enormous experience in cancer drug discovery."